journal
MENU ▼
Read by QxMD icon Read
search

Lancet Diabetes & Endocrinology

journal
https://www.readbyqxmd.com/read/30005958/incidence-and-progression-of-diabetic-retinopathy-a-systematic-review
#1
REVIEW
Charumathi Sabanayagam, Riswana Banu, Miao Li Chee, Ryan Lee, Ya Xing Wang, Gavin Tan, Jost B Jonas, Ecosse L Lamoureux, Ching-Yu Cheng, Barbara E K Klein, Paul Mitchell, Ronald Klein, C M Gemmy Cheung, Tien Y Wong
Diabetic retinopathy is a leading cause of vision impairment and blindness. We systematically reviewed studies published from Jan 1, 1980, to Jan 7, 2018, assessed the methodological quality, and described variations in incidence of diabetic retinopathy by region with a focus on population-based studies that were conducted after 2000 (n=8, including two unpublished studies). Of these eight studies, five were from Asia, and one each from the North America, Caribbean, and sub-Saharan Africa. The annual incidence of diabetic retinopathy ranged from 2·2% to 12·7% and progression from 3·4% to 12·3%...
July 10, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29937268/renal-outcomes-in-cvots-keep-calm-and-carry-on
#2
Marcel H A Muskiet, Michaël J B van Baar, Rosalie A Scholtes, Daniël H van Raalte
No abstract text is available yet for this article.
June 21, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29937267/canagliflozin-and-renal-outcomes-in-type-2-diabetes-results-from-the-canvas-program-randomised-clinical-trials
#3
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews, Bruce Neal
BACKGROUND: In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, canagliflozin reduced the rates of major adverse cardiovascular events and the results suggested a renal benefit in patients with type 2 diabetes who were at high risk for cardiovascular events, compared with those treated with placebo. Here we report the results of a prespecified exploratory analysis of the long-term effects of canagliflozin on a range of sustained and adjudicated renal outcomes. METHODS: The CANVAS Program consists of two double-blind, randomised trials that assessed canagliflozin versus placebo in participants with type 2 diabetes who were at high risk of cardiovascular events, done at 667 centres in 30 countries...
June 21, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29910025/dulaglutide-and-renal-protection-in-type-2-diabetes
#4
David Z I Cherney, Subodh Verma, John D Parker
No abstract text is available yet for this article.
June 14, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29910024/dulaglutide-versus-insulin-glargine-in-patients-with-type-2-diabetes-and-moderate-to-severe-chronic-kidney-disease-award-7-a-multicentre-open-label-randomised-trial
#5
Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Robert S Busch, Alan G Zimmermann, D Bradley Woodward, Fady T Botros
BACKGROUND: Many antihyperglycaemic drugs, including insulin, are primarily cleared by the kidneys, restricting treatment options for patients with kidney disease. Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist that is not cleared by the kidneys, and confers a lower risk of hypoglycaemia than does insulin. We assessed the efficacy and safety of dulaglutide in patients with type 2 diabetes and moderate-to-severe chronic kidney disease. METHODS: AWARD-7 was a multicentre, open-label trial done at 99 sites in nine countries...
June 14, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29884469/stress-at-work-in-patients-with-cardiometabolic-disease
#6
Yulong Lian
No abstract text is available yet for this article.
June 5, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29884468/work-stress-and-risk-of-death-in-men-and-women-with-and-without-cardiometabolic-disease-a-multicohort-study
#7
Mika Kivimäki, Jaana Pentti, Jane E Ferrie, G David Batty, Solja T Nyberg, Markus Jokela, Marianna Virtanen, Lars Alfredsson, Nico Dragano, Eleonor I Fransson, Marcel Goldberg, Anders Knutsson, Markku Koskenvuo, Aki Koskinen, Anne Kouvonen, Ritva Luukkonen, Tuula Oksanen, Reiner Rugulies, Johannes Siegrist, Archana Singh-Manoux, Sakari Suominen, Töres Theorell, Ari Väänänen, Jussi Vahtera, Peter J M Westerholm, Hugo Westerlund, Marie Zins, Timo Strandberg, Andrew Steptoe, John Deanfield
BACKGROUND: Although some cardiovascular disease prevention guidelines suggest a need to manage work stress in patients with established cardiometabolic disease, the evidence base for this recommendation is weak. We sought to clarify the status of stress as a risk factor in cardiometabolic disease by investigating the associations between work stress and mortality in men and women with and without pre-existing cardiometabolic disease. METHODS: In this multicohort study, we used data from seven cohort studies in the IPD-Work consortium, initiated between 1985 and 2002 in Finland, France, Sweden, and the UK, to examine the association between work stress and mortality...
June 5, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29884467/the-earlier-the-better-preconception-vitamin-d-and-protection-against-pregnancy-loss
#8
Martin Hewison
No abstract text is available yet for this article.
June 5, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29880308/effectiveness-and-safety-of-long-term-treatment-with-sulfonylureas-in-patients-with-neonatal-diabetes-due-to-kcnj11-mutations-an-international-cohort-study
#9
Pamela Bowman, Åsta Sulen, Fabrizio Barbetti, Jacques Beltrand, Pernille Svalastoga, Ethel Codner, Ellen H Tessmann, Petur B Juliusson, Torild Skrivarhaug, Ewan R Pearson, Sarah E Flanagan, Tarig Babiker, Nicholas J Thomas, Maggie H Shepherd, Sian Ellard, Iwar Klimes, Magdalena Szopa, Michel Polak, Dario Iafusco, Andrew T Hattersley, Pål R Njølstad
BACKGROUND: KCNJ11 mutations cause permanent neonatal diabetes through pancreatic ATP-sensitive potassium channel activation. 90% of patients successfully transfer from insulin to oral sulfonylureas with excellent initial glycaemic control; however, whether this control is maintained in the long term is unclear. Sulfonylurea failure is seen in about 44% of people with type 2 diabetes after 5 years of treatment. Therefore, we did a 10-year multicentre follow-up study of a large international cohort of patients with KCNJ11 permanent neonatal diabetes to address the key questions relating to long-term efficacy and safety of sulfonylureas in these patients...
June 4, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29880307/precision-medicine-in-kcnj11-permanent-neonatal-diabetes
#10
Siri Atma W Greeley, Lisa R Letourneau, Louis H Philipson
No abstract text is available yet for this article.
June 4, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29859910/obesity-is-rarely-healthy
#11
Carl J Lavie, Prakash Deedwania, Francisco B Ortega
No abstract text is available yet for this article.
May 30, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29859909/association-of-preconception-serum-25-hydroxyvitamin-d-concentrations-with-livebirth-and-pregnancy-loss-a-prospective-cohort-study
#12
Sunni L Mumford, Rebecca A Garbose, Keewan Kim, Kerri Kissell, Daniel L Kuhr, Ukpebo R Omosigho, Neil J Perkins, Noya Galai, Robert M Silver, Lindsey A Sjaarda, Torie C Plowden, Enrique F Schisterman
BACKGROUND: Vitamin D deficiency during pregnancy is associated with adverse pregnancy outcomes, although the association between preconception vitamin D concentrations and livebirth is unknown. We aimed to assess the association between preconception vitamin D and pregnancy outcomes among women with proven fecundity. METHODS: We did a secondary analysis of a prospective cohort from the block-randomised, double-blind, placebo-controlled EAGeR trial. Women aged 18-40 years with one to two previous pregnancy losses were recruited from June 15, 2007, to July 15, 2011, at four clinical sites in the USA and followed up for up to six menstrual cycles while attempting pregnancy and throughout pregnancy if they conceived...
May 30, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29859908/transition-from-metabolic-healthy-to-unhealthy-phenotypes-and-association-with-cardiovascular-disease-risk-across-bmi-categories-in-90-257-women-the-nurses-health-study-30-year-follow-up-from-a-prospective-cohort-study
#13
Nathalie Eckel, Yanping Li, Olga Kuxhaus, Norbert Stefan, Frank B Hu, Matthias B Schulze
BACKGROUND: Cardiovascular disease risk among individuals across different categories of BMI might depend on their metabolic health. It remains unclear to what extent metabolic health status changes over time and whether this affects cardiovascular disease risk. In this study, we aimed to examine the association between metabolic health and its change over time and cardiovascular disease risk across BMI categories. METHODS: Between June and December, 1976, 121 701 female nurses were recruited to the Nurses' Health Study (NHS) of whom 103 298 returned a questionnaire in 1980 used as baseline in this study...
May 30, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29807825/preferred-strategy-for-postsurgical-thyroid-ablation-in-low-risk-thyroid-cancer
#14
Furio Pacini
No abstract text is available yet for this article.
May 25, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29807824/outcome-after-ablation-in-patients-with-low-risk-thyroid-cancer-estimabl1-5-year-follow-up-results-of-a-randomised-phase-3-equivalence-trial
#15
Martin Schlumberger, Sophie Leboulleux, Bogdan Catargi, Desiree Deandreis, Slimane Zerdoud, Stephane Bardet, Daniela Rusu, Yann Godbert, Camille Buffet, Claire Schvartz, Pierre Vera, Olivier Morel, Danielle Benisvy, Claire Bournaud, Marie-Elisabeth Toubert, Antony Kelly, Ellen Benhamou, Isabelle Borget
BACKGROUND: In ESTIMABL1, a randomised phase 3 trial of radioactive iodine (131 I) administration after complete surgical resection in patients with low-risk thyroid cancer, 92% of patients had complete thyroid ablation at 6-10 months, defined as a recombinant human thyroid-stimulating hormone (rhTSH)-stimulated serum thyroglobulin concentration of 1 ng/mL or less and normal findings on neck ultrasonography. Equivalence was shown between low-activity (1·1 GBq) and high-activity (3·7 GBq) radioactive iodine and also between the use of rhTSH injections and thyroid hormone withdrawal...
May 25, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29799414/psoriasis-a-novel-risk-factor-for-type-2-diabetes
#16
Joel M Gelfand, Marilyn T Wan
No abstract text is available yet for this article.
May 21, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29754897/correction-to-lancet-diabetes-endocrinol-2018-published-online-may-4-http-dx-doi-org-10-1016-s2213-8587-18-30105-0
#17
(no author information available yet)
No abstract text is available yet for this article.
May 10, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29735394/dorzagliatin-monotherapy-in-chinese-patients-with-type-2-diabetes-a-dose-ranging-randomised-double-blind-placebo-controlled-phase-2-study
#18
Dalong Zhu, Shenglian Gan, Yu Liu, Jianhua Ma, Xiaolin Dong, Weihong Song, Jiao'e Zeng, Guixia Wang, Wenjuan Zhao, Qiu Zhang, Yukun Li, Hui Fang, Xiaofeng Lv, Yongquan Shi, Haoming Tian, Linong Ji, Xin Gao, Lihui Zhang, Yuqian Bao, Minxiang Lei, Ling Li, Longyi Zeng, Xiaoying Li, Xinghua Hou, Yu Zhao, Tianxin Hu, Xiaoyun Ge, Guiyu Zhao, Yongguo Li, Yi Zhang, Li Chen
BACKGROUND: Glucokinase acts as a glucose sensor in the pancreas and a glucose processor in the liver, and has a central role in glucose homoeostasis. Dorzagliatin is a new, dual-acting, allosteric glucokinase activator that targets both pancreatic and hepatic glucokinases. Dorzagliatin has good pharmacokinetic and pharmacodynamic properties in humans, and provides effective 24-h glycaemic control and improves glucose sensitivity in patients with type 2 diabetes. We aimed to assess the efficacy and safety of dorzagliatin monotherapy at different doses in Chinese patients with type 2 diabetes...
May 4, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29735393/new-hope-for-glucokinase-activators-in-type-2-diabetes
#19
André J Scheen
No abstract text is available yet for this article.
May 4, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29699867/precision-medicine-in-the-management-of-type-2-diabetes
#20
REVIEW
Anna L Gloyn, Daniel J Drucker
The study of type 2 diabetes has been driven by advances in human genetics, epigenetics, biomarkers, mechanistic studies, and large clinical trials, enabling new insights into disease susceptibility, pathophysiology, progression, and development of complications. Simultaneously, several new drug classes with different mechanisms of action have been introduced over the past two decades, accompanied by data about cardiovascular safety and non-glycaemic outcomes. In this Review, we critically examine the progress and integration of this new science into clinical practice, and review opportunities for enabling the use of precision medicine in the diagnosis and treatment of type 2 diabetes...
April 23, 2018: Lancet Diabetes & Endocrinology
journal
journal
47944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"